Practical Radiation Oncology Program 2024
This program is designed to address the needs of a community practice physician and includes disease site reviews, interactive case-based discussions, a business fundamentals review and a radiopharmaceuticals overview.
Target Audience
The activity is designed to meet the interests of medical oncologists, radiation oncologists, surgeons, nurses, radiation dosimetrists, physicists, pathologists, residents, neurosurgeons, diagnostic radiologists, radiation therapists, practice managers, dietitians and urologists.
Learning Objectives
Upon completion of this activity, participants should be able to do the following:
- Discuss treatment options for patients with early stage breast cancer and those treated with neoadjuvant chemotherapy.
- Discuss indications and treatment techniques for IMRT in breast cancer patients.
- Develop a framework for selecting the optimal treatment for patients with brain metastases.
- Increase the tools for diagnosis and management of radionecrosis.
- Best counsel patients on risk of neurotoxicity and options for mitigating and managing the toxicity.
- Describe the necessary components of maintaining a clinical practice.
- Create a business plan advocating for a new technology or treatment.
- Partner with clinic, hospital and organizational leaders to promote best practices in radiation oncology.
- Have evidence basis and comfort in treating osteoarthritis and plantar fasciitis with LD-RT.
- Have evidence basis and comfort in treating other musculoskeletal/connective tissue disorders such as Dupuytren's and Lederhosen's.
- Have understanding of potential treatments for tremors, dementia, depression.
- Describe three different intentions of radiotherapy: curative, disease-modifying and palliative radiotherapy.
- List the essential components of having time-sensitive, meaningful conversations with patients and families about goals and values that can influence radiotherapy decision making.
- Determine the appropriate dose constraints to be utilized in common clinical situations including SBRT to central and peripheral lung lesions.
- Assess common side effects of lung treatment and determine appropriate management.
- Describe the molecular pathologic features that should be included in pathology report for endometrial, vulvar and cervix cancers.
- Be able to discuss how pathologic factors, such as molecular status, influence prognosis and treatment decisions.
- Discuss recent clinical trial data for the management of gynecologic cancers and define what patient populations show survival benefits with these new approaches, such as immunotherapy.
- Be aware of the motivation and evidence for treating suitable prostate patients with SBRT.
- Feel confident in contouring, treatment planning and delivery of prostate SBRT. Be cognizant of tips to reducing side effects.
- Be familiar with approaches to building a successful community prostate SBRT program including advice on successful team building, marketing and reimbursement.
- Explain planning techniques to prevent treatment related side effects from head and neck cancer radiation.
- Describe management techniques to treat acute and late side effects from radiation to the head and neck.
- Identify indications for radiopharmaceuticals for prostate cancer.
- Identify resources needed to implement radiopharmaceuticals in a community clinic.
The program is comprised of ten sessions:
- Advances in Breast Cancer Management: Early-Stage Disease, Post-Neoadjuvant Radiation Therapy and IMRT for Breast Cancer Treatment
- To Treat or Not To Treat: Patients with Early Stage Breast Cancer - Janice Lyons, MD
- Radiation Therapy for Breast Cancer Patients Treated with Neoadjuvant Chemotherapy - Lisa Singer, MD, PhD
- Indications and Techniques for Breast IMRT - Laura Warren, MD
- Brain Metastases Radiotherapy while Mitigating Radionecrosis and Neurotoxicity
- Tailored Approach to Brain Metastases Management - Stuart Burri, MD
- Mitigating and Managing Neurotoxicity from Radiotherapy for Brain Metastases - William Breen, MD
- Prevention and Management Strategies for Radionecrosis - Raj Singh, MD
- Business of Radiation Oncology for Clinicians
- Running a Private Practice - Christopher Jahraus, MD
- How to Be a Partner with Your Business Manager - Curtiland Deville, MD, FASTRO
- How to Build a Business Plan - Becki Swanson, OCN, BSN, RN, MSHA
- What Academicians Need to Know About the Business of Radiation Oncology - Kimberly Smith, MPA
- Benign Radiotherapy: Back to the Future
- LDRT for Osteoarthritis and Plantar Fasciitis - Nagendra (Bobby) Koneru, MD, FASTRO
- Pain, Pain, Go Away...LD-RT in Dupuytrens Contracture and Other Musculoskeletal Disorders - Mudit Chowdhary, MD
- Benign CNS: Opportunities and State of the Art - Jona Hattangadi-Gluth, MD, FASTRO
- Patient Guided Radiotherapy: Tools to Help Providers Support Patients when the "Right Choice" Isn't Always Clear
- Goals of Care Conversations for the Radiation Oncologist - Emily Martin, MD
- Defining Radiotherapy Intent - Joshua Jones, MD
- Prevention and Management of Toxicity in Organs at Risk (OAR)
- Lung OAR: Conventional Fractionated Treatment - Julianna Bronk, MD, PhD
- Lung OAR: Central and Ultracentral SBRT - Matthew Ning, MD, MPH
- Lung OAR: Peripheral Lung SBRT - Shane Mesko, MD, MBA
- Gynecologic Tumor Board - Case-Based Discussion of the Molecular and Treatment Approach Updates for the Management of Endometrial, Vulvar and Cervical Cancers
- Gynecologic Molecular Pathology Review for Endometrial, Vulvar and Cervix Cancers - Taylor Jenkins, MD
- Endometrial Cancer Staging and Treatment Updates - The Significance of Pathology and Molecular Status - Susan Gueble, MD, PhD
- Vulvar and Cervical Cancer Treatment Updates - Junzo Chino, MD, FASTRO
- Implementation of a Prostate SBRT Program in the Community Setting
- Evidence that SBRT is a New Standard of Care for Localized Prostate Cancer - Nicholas van As, MD, MB
- Building a Successful Community Prostate SBRT Practice - Jonathan Haas, MD
- How to Safely Deliver Prostate SBRT in a Community Setting - Michael Zelefsky, MD, FASTRO
- Head and Neck Cancer - Prevention and Management of Radiation Therapy Toxicity
- Reduction in Head and Neck Cancer Toxicity: Simulation and Planning Considerations - Shauna Campbell, MD, DO
- Management of Acute Toxicity from Head and Neck Radiation Therapy - Carryn Anderson, MD, FASTRO
- Treatment of Late Toxicity from Head and Neck Radiation Therapy - Darrion Mitchell, MD, PhD
- Introduction to Theranostics for the Community Radiation Oncologist
- Radiopharmaceuticals for Prostate Cancer - Jeff Michalski, MD, MBA, FASTRO
- Delivering Radiopharmaceuticals within a Radiation Oncology Clinic - Youssef Charara, PhD
- Implementing a Multidisciplinary Theranostics Program in a Community Setting - Brandon Mancini, MD, MBA
This activity is available from December 2, 2024, through 11:59 p.m. Eastern time on December 31, 2025.
This activity was originally recorded at the 2024 ASTRO Annual Meeting.
Faculty:
Name | Employment Relationships | Consulting or Advisory Board/Speaker/Faculty/Research/Honoraria | Ownerships/Investments/Intellectual Property | Leadership/Positions of Authority |
Carryn Anderson | Heartland Anesthesia: Chief Operating Officer: Employee University of Iowa Hospitals & Clinics: Radiation Oncologist: Employee | Galera Therapeutics, Inc: Consultant, Research: Recipient: My Institution: Salary Support: No: site principal investigator: Drug development to mitigate oral mucositis: Compensation/Payment, Uncompensated: Member of consulting focus group for development of healthcare provider and patient education materials related to potential commercial launch of avasopasem manganese for oral mucositis in head and neck cancer patients receiving cisplatin & RT.: Present | None | University of Iowa Hospitals & Clinics: Residency Program Director: Maintain ACGME accreditation for Radiation Oncology program: Compensation? No: Relationship ended 03/30/2023 |
William Breen | Mayo Clinic: Radiation Oncologist: Employee | GE Healthcare: Advisory Board: Single: Access to company proprietary information or provide your expertise; or any public-facing use of your name/image: No: Compensation/Payment, Other-Paid to institution: Discussion of development of novel PET/CT radiotracers, all funds paid to department.: January 2023 Miltenyi: Advisory Board: Single: Access to company proprietary information or provide your expertise; or any public-facing use of your name/image: No: Compensation/Payment, Other-Paid to institution: CAR-T development for CNS lymphoma: 5/29/24 | None | None |
Julianna Bronk | University of Texas MD Anderson Cancer Center: Assistant Professor: Employee | None | None | None |
Stuart Burri | Southeast Radiation Oncology Group: President and Partner: Partner | Novocure: Other-Data Safety monitoring committee: Travel expenses, Compensation/Payment: Member of data safety monitoring board for the METIS trial: 2023 | Charlotte Physics Holding: Ownership equity: Partial owner of holding company that owns an interest in a physics staffing company FUSE Oncology Holding: Ownership equity: Own a partial stake of a holding company that owns a portion of FUSE Oncology Oncology Practice Solutions: Ownership equity: Own a portion and am a managing partner of Oncology Practice Solutions Radiation Oncology Centers of the Carolinas: Ownership equity: Partial owner Southeast Radiation Oncology Group: Partnership: President and partner | Atrium Health - Levine Cancer Institute: A large non-profit health system: Chairman of Radiation Oncology: Chairman of Radiation Oncology: Compensation? No |
Shauna Campbell | Cleveland Clinic Foundation: Radiation Oncologist: Employee | None | None | None |
Youssef Charara | Howard University: Adjunct professor: Employee: May 2024 Virginia Cancer Specialists: Chief Medical Physicist: Employee | Novartis/aaa: Consultant: Compensation/Payment, Other-TBD: consultant on RLT experience: Present | None | None |
Junzo Chino | Duke University Health System: Associate Professor: Employee | GOG Foundation: Other-Received Stipend for writing (GOG foundation book): Honoraria: Honoraria for writing: 4/10/23 Guidepoint: Consultant: Compensation/Payment: Investment Consulting - Platinum Therapy: 10/9/23 KM Pharmaceutical Consulting LLC: Other-Data and Safety Monitoring Board for ongoing trial: Honoraria: Data and Safety Monitoring Board for ongoing trial for Cervical Cancer: To present Merck: Advisory Board: Single: Access to company proprietary information or provide your expertise; or any public-facing use of your name/image: No: Grant/research funding: Pembrolizumab in Cervical Cancer: 1/22/24 Stryker: Consultant: Honoraria: Airo CT Consulting: 4/30/23 | None | American Brachytherapy Society: Medical Society: Board Member: Board Member: Compensation? No |
Mudit Chowdhary | Northside Hospital: Radiation Oncologist: Employee | None | None | None |
Christine Chung | Alta Bates Comprehensive Cancer Center; H. Lee Moffitt Cancer Center | None | None | None |
Sean Collins | Department of Radiation Medicine, MedStar Georgetown University Hospital | Accuray: Consultant: Honoraria: clinical consultation: Present | None | None |
Curtiland Deville | Johns Hopkins University: Associate Professor: Employee | None | None | ASTRO: Vice Chair, Council on Health Equity, Diversity & Inclusion: Board of Directors: Compensation? No ASTRO Red Journal: Deputy Editor: Deputy Editor: Compensation? No |
Virginia Diavolitsis | Ohio State University: Physician: Partner Riverside Radiation Oncology: Physician: Partner | None | None | None |
Beant Gill | Associates in Radiation Medicine: Physician: Partner Luminis Health: Physician: Employee | The George Washington University: Other-Faculty: Uncompensated: Clinical role for mentorship and teaching students: Present | Associates in Radiation Medicine: Ownership equity: Partner: Partnership: Partner: Ownership equity: Partner: Partnership: Partner | American College of Radiology: Organization for radiology and radiation oncology: CAC Representative: Representative for local coverage determination review of radiation oncology services: Compensation? No Chesapeake Potomac Regional Cancer Center: Community practice for radiation oncology services: Medical Director: Medical director for clinical operations: Compensation? No |
Susan Gueble | Yale School of Medicine: Assistant Professor: Employee Yale-New Haven Hospital: Radiation Oncology Resident: Employee: Relationship ended 06/30/2023 | National Institutes of Health: Research: Recipient: Me: Salary Support: Yes: national/overall principal investigator: Basic/translational oncology research: Grant/research funding, Salary support: Principal Investigator on NIH Grant 1DP5OD036128 "Therapeutic Potential of a Novel MGMT-Dependent DNA Interstrand Crosslinking Agent in the Treatment of DNA Repair Deficient Cancer": 7/31/2028 Spector Family Fund for Clinical Research and Investigation: Research: Recipient: Me: Salary Support: No: Principal Investigator on Internal Award: Basic/translational oncology research: Grant/research funding: Principal Investigator on Spector Family Fund for Clinical Research and Investigation and Yale Physician Scientist Development Internal Award "Overcoming Temozolomide Resistance with a Novel MGMT-Dependent DNA Interstrand Crosslinking Agent in Non-Glioma Cancers": 6/30/2025 Yale SPORE in Skin Cancer: Research: Recipient: Me: Salary Support: No: Principal Investigator on Internal Award: Basic/translational oncology research: Grant/research funding: Principal Investigator on Career Enhancement Program Internal Award from Yale SPORE in Skin Cancer "Defining the Interactions of a Novel DNA Modifying Agent with Melanoma-Specific Genetic Features and Molecular Targeted Agents": 8/31/2024 | Modifi Biosciences: Copyright/Patent/License/Royalty: Receive royalty distribution of licensing for "Mechanism of action of KL-50 a lead compound for the treatment of drug-resistant glioblastoma" | Yale Cancer Center: Neuroendocrine Tumor Program Steering Committee: Member: Member of the Yale Cancer Center Neuroendocrine Tumor Program Steering Committee: Compensation? No |
Jonathan Haas | NYU Langone Hospital-Long Island: Chairman: Employee | Accuray: Education/Meeting Faculty, Speaker's Bureau: Honoraria: speaker: Present | None | None |
Jona Hattangadi-Gluth | UC San Diego/Moores Cancer Center: Professor: Employee | None | None | None |
Christopher Jahraus | Generations Radiotherapy & Oncology PC: Owner & Physician: Partner | Elekta: Consultant, Advisory Board, Speaker's Bureau: Ongoing: Access to company proprietary information or provide your expertise; or any public-facing use of your name/image: Yes: Honoraria, Travel expenses, Compensation/Payment: I have spoken about their product SmartClinic in numerous venues and served on multiple customer advisory committees.: To Present RADformation: Consultant: Other-Provision of software.: I have worked with RADformation to assist them in developing their products in the Elekta OIS environment.: To Present | Drug Patent: Ownership equity: I am co-maker of a patent for use of rifaximin in radiotherapy patients. Patents have been granted in Canada, the European Union (including Spain specifically), Israel, Japan, Korea, and Russia. I have received no money whatsoever for this intellectual property nor for my rights to it.: Relationship ended 05/08/2024 Generations Radiotherapy & Oncology PC: Ownership equity: I am 100% owner of my practice.: Relationship ended 05/08/2024 | American College of Radiation Oncology: I am a very active member of ACRO (and ASTRO). Within ACRO, I serve multiple roles, including those shown below.: Vice Chair, Gov't Relations & Economics Committee; Vice Chair, PAC; Deputy Editor of Journal Channel (CURiE); Chair, ACROPath; RUC-Advisor: I am a member of this organization and actively participate on a voluntary basis, frequently cooperating with ASTRO leadership in my roles at ACRO.: Compensation? No: Relationship ended 05/08/2024 |
Taylor Jenkins | VCU: Assistant Professor: Employee | None | None | None |
Joshua Jones | Children's Hospital of Philadelphia: Pediatrician: Employee: Relationship ended 06/30/2023 Pediatric Urgent Car of Rochester: Pediatrician: Employee Rochester Regional Health: Radiation Oncologist: Employee University of Pennsylvania Health System: Associate Professor of Radiation Oncology: Employee: Relationship ended 05/12/2023 | None | None | None |
Elizabeth Kidd | Stanford University: Associate Professor: Employee | Viewray: Research: Recipient: My Institution: Salary Support: No: site principal investigator: Use of viewray for fractionated radiation: Grant/research funding: Use of viewray for cervix cancer fractionated radiation: Aug. 2023 | None | ABS Quality & Safety Standard Committee: Co-Leader: Oversee the ABS Quality and Safety Standards Committee.: Compensation? No |
Nagendra (Bobby) Koneru | Leonard C. Ferguson Cancer Center: Radiation Oncologist: Employee | IORBC: Advisory Board: Ongoing: Access to company proprietary information or provide your expertise; or any public-facing use of your name/image: Yes: Uncompensated: Board Member: Present | None | None |
Janice Lyons | University Hospitals Seidman Cancer Center: Radiation Oncologist: Employee | Primum: Other-I serve as a breast cancer expert answering questions posed by the community physicians: Honoraria: I receive compensation for each question answered.: Present | None | ABR: ABR exam development: Member: Help develop the ABR oral exam and administer the ABR oral exam: Compensation? No ASTRO: ASTRO PBI guideline: Chair: Chairing the PBI guideline committee: Compensation? No NCCN: NCCN breast cancer guideline committee: Member: Help update the breast cancer guidelines, review the radiation compendium: Compensation? No |
Brandon Mancini | BAMF Health: Medical Director: Employee West Michigan Cancer Center: Radiation Oncologist: Employee: Relationship ended 03/13/2022 | GE HealthCare: Advisory Board, Speaker's Bureau: Ongoing: Access to company proprietary information or provide your expertise; or any public-facing use of your name/image: Yes: Honoraria, Travel expenses: Speaker's Bureau with industry presentation at the 2023 SNMMI Annual Meeting on the advancement of radiopharmaceutical treatment/care. Asked to serve on a Theranostics Advisory Board.: To Present GoodRx Health: Consultant: Compensation/Payment: Ad hoc editing/revision of prostate cancer-related educational articles: To Present MCG Health: Consultant: Compensation/Payment: Consultant to evaluate and edit/revise medical guidelines.: To Present | BAMF Health, Inc.: Ownership equity: Medical Director | BAMF Health: Medical Director: Serve as Medical Director in addition to primary role as a physician providing patient care.: Compensation? No |
Emily Martin | University of California, Los Angeles: Assistant Clinical Professor: Employee | None | None | None |
Shane Mesko | Scripps Cancer Center: Radiation Oncologist: Employee | Oscar Health: Consultant: Compensation/Payment: Independent Consultant for coverage guidelines: To Present | None | None |
Jeff Michalski | Washington University School of Medicine: Professor: Employee | Michalski and Associates: Consultant: Travel expenses, Compensation/Payment: Consultatn: To present NCI: Research: Recipient: My Institution: Salary Support: No: co-investigator: Radium-223; Improving Response and Toxicities: Grant/research funding: Coinvestigator: To present | None | NCI: GU Steering Committee: Co-Chair: Oversee portfolio of NCI NCTN clinical trials in genitourinary cancers.: Compensation? No RTOG Foundation: nonprofit organization dedicated to improving outcomes for cancer patients through the conduct of practice changing clinical trials.: Treasurer: Treasurer and board of directors: Compensation? No |
Darrion Mitchell | The Ohio State University: Assistant Professor: Employee | None | None | None |
Matthew Ning | UT MD Anderson Cancer Center: Assistant Professor: Employee | None | None | None |
Simul Parikh | Lake Huron Medical Center: Radiation Oncologist: Employee | None | None | None |
Christopher Hays Pope | CARTI | None | None | None |
Malolan Rajagopalan | Mount Carmel Health System; Radiology, Inc. | None | None | None |
Avani Rao | Radiation Oncology Associates of the National Capital Region: Associate: Employee | None | None | None |
Arshin Sheybani | UnityPoint Health: Physician: Employee | None | None | ASTRO: Nominating Committee: community practice physician: member of ASTRO nominating committee for leadership appointments: Compensation? No ASTROnews: magazine publication for ASTRO: editorial board member: select topics for publication: Compensation? No IWORC-NCORP: review NCORP grant: board member: voting member to designate inclusion of cancer centers and providers into our NCORP: Compensation? No Rectal Anal Task Force: a subcommittee of the NCI GI steering committee: community oncologist representative: a member of the committee with 3 year term. we have monthly meetings to discuss development of clinical trials for rectal and anal cancers: Compensation? No |
Lisa Singer | University of California, San Francisco: Assistant Professor: Employee | UCSF PIPE: Research: Recipient: Me: Salary Support: Yes: site principal investigator: Simulation-Based Education: Grant/research funding: Simulation-Based Education: 6/30/2023 | None | American Board of MR Safety: Board of Directors: Board of Directors: Board of Directors: Compensation? No |
Raj Singh | The Ohio State University Wexner Medical Center: Assistant Professor/Physician: Employee Virginia Commonwealth University Health System: Resident Physician: Employee: Relationship ended 06/30/2023 | None | None | None |
Kimberly Smith | Department of Radiation Oncology, Icahn School of Medicine at Mount Sinai | Elekta: Advisory Board: Ongoing: Access to company proprietary information or provide your expertise; or any public-facing use of your name/image: No: Travel expenses, Compensation/Payment: Serve as member on advisory board providing operational feedback to assist company in the production of software to assist in workflow efficiencies.: Present | None | None |
Becki Swanson | AdventHealth: Executive Director Cancer Institute: Employee | None | None | None |
Nicholas van As | The Royal Marsden NHS Foundation Trust | Accuray: Education/Meeting Faculty, Speaker's Bureau: Grant/research funding: Chief investigator: 2025 | None | None |
Laura Warren | Brigham and Women's Physician Organization: Physician: Employee | None | None | None |
Michael Zelefsky | Memorial Sloan Kettering Cancer Center: Attending Physician: Employee: Relationship ended 04/01/2024 NYU Langone Medical Center: Attending Physician: Employee | Boston Scientific: Consultant: Compensation/Payment: Consultant: Present | None | Brachytherapy Journal: Journal: Editor in Chief: Editor/Manuscripts: Compensation? Yes |
Planners:
The person(s) above served as the developer(s) of this activity. Additionally, the ASTRO Education Commitee had control over the content of this activity.
All relevant financial relationships have been mitigated.
The American Society for Radiation Oncology (ASTRO) is accredited by the Accreditation Council of Continuing Medical Education to provide continuing education to physicians.
Available Credit
- 12.50 AMA PRA Category 1 Credit™
The American Society for Radiation Oncology (ASTRO) is accredited by the Accreditation Council for Continuing Medical Education for physicians. ASTRO designates this Enduring material for a maximum of 12.50 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
- 12.50 Certificate of AttendanceThis activity was designated for 12.50 AMA PRA Category 1 Credit™.
Price
Course Fees:
ASTRO members must log in to the ASTRO website to view and receive the discounted member rate.
Nonmember: $699
Member: $599
Postdoctoral Fellow Member: $299
Member-in-Training: $299
Student/Grad Student/PGY-1 Member: $299
If you are an ASTRO member from a low or lower-middle income country, as identified by the World Bank, you can receive a 50% discount off your corresponding registration for this activity. Please email [email protected] to inquire about the discount.
Policies:
No refunds, extensions, or substitutions will be made for those registrants. Including those who for any reason, have not completed the course by the end of the qualification date. The qualification date for each course is listed in the course catalog on the ASTRO website under availability.
Participants using ASTRO's online courses to satisfy the requirement of a Maintenance of Certification (MOC) program should verify the number, type and availability dates of any course before making a purchase. No refunds, extensions, or substitutions will be made for participants who have purchased courses that do not align with their MOC requirement
The course and its materials will only be available on the ASTRO website until December 31, 2025 regardless of purchase date. At the expiration of the qualification, participants will no longer have access to the course or its materials. ASTRO reserves the right to remove a course before the end of its qualification period.
Required Hardware/software
One of the two latest versions of Google Chrome, Mozilla Firefox, Internet Explorer or Safari.